Pfizer (PFE) Extends Expiration on $6/Share Takeover of Icagen (ICGN)
Tweet Send to a FriendGet Alerts PFE Hot Sheet
Price: $28.78 +0.28%
Overall Analyst Rating:
BUY (
Up)
Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Overall Analyst Rating:
BUY (
Up)Dividend Yield: 3.5%
Revenue Growth %: -12.3%
Trade PFE Now!
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The tender offer is now scheduled to expire at 12:00 midnight, New York City time, at the end of Thursday, September 1, 2011, unless further extended.
The tender offer was previously scheduled to expire at 12:00 midnight, New York City time, at the end of Wednesday, August 31, 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The tender offer was previously scheduled to expire at 12:00 midnight, New York City time, at the end of Wednesday, August 31, 2011.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Royalty Pharma Raises Elan (ELN) Bid to $12.50/share
- UPDATE: Correct: Buying Warner Chilcott plc (WCRX) Seen as Takeover Defense by Actavis (ACT)
- Paulson in Favor of Amended Plains Exploration (PXP), Freeport (FCX) Merger
Create E-mail Alert Related Categories
Corporate News, Mergers and Acquisitions
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
